These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24308279)

  • 1. Pramipexole augmentation in treatment-resistant major depressive disorder.
    Pae CU
    Expert Rev Neurother; 2014 Jan; 14(1):5-8. PubMed ID: 24308279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
    Cusin C; Iovieno N; Iosifescu DV; Nierenberg AA; Fava M; Rush AJ; Perlis RH
    J Clin Psychiatry; 2013 Jul; 74(7):e636-41. PubMed ID: 23945458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder.
    Cha DS; Luo X; Ahmed J; Becirovic L; Cha RH; McIntyre RS
    Expert Rev Neurother; 2019 Sep; 19(9):777-783. PubMed ID: 31389279
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study.
    Tundo A; Betro' S; Iommi M; de Filippis R
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jan; 112():110425. PubMed ID: 34375683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
    Connolly KR; Thase ME
    Drugs; 2011 Jan; 71(1):43-64. PubMed ID: 21175239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.
    Chang CM; Sato S; Han C
    CNS Drugs; 2013 May; 27 Suppl 1():S21-7. PubMed ID: 23712796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.
    Au-Yeung SK; Griffiths J; Roberts S; Edwards C; Yu LM; Bogacz R; Rendell J; Attenburrow MJ; Watson S; Chan F; Cipriani A; Cleare A; Harmer CJ; Kessler D; Evans J; Lewis G; Singh I; Simon J; Harrison PJ; Cowen P; Shanyinde M; Geddes J; Browning M
    Evid Based Ment Health; 2022 May; 25(2):77-83. PubMed ID: 34810175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
    Fawcett J; Rush AJ; Vukelich J; Diaz SH; Dunklee L; Romo P; Yarns BC; Escalona R
    Am J Psychiatry; 2016 Feb; 173(2):107-11. PubMed ID: 26844792
    [No Abstract]   [Full Text] [Related]  

  • 13. Antidepressant augmentation and combinations.
    Dording CM
    Psychiatr Clin North Am; 2000 Dec; 23(4):743-55. PubMed ID: 11147245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.
    Goldberg JF; Burdick KE; Endick CJ
    Am J Psychiatry; 2004 Mar; 161(3):564-6. PubMed ID: 14992985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole: augmentation in the treatment of depressive symptoms.
    Gupta S; Vincent JL; Frank B
    CNS Spectr; 2006 Mar; 11(3):172-5. PubMed ID: 16575373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.
    Dold M; Bartova L; Mendlewicz J; Souery D; Serretti A; Porcelli S; Zohar J; Montgomery S; Kasper S
    Acta Psychiatr Scand; 2018 May; 137(5):401-412. PubMed ID: 29492960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S; Gutwinski S; Bschor T
    Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.
    Zhdanava M; Karkare S; Pilon D; Joshi K; Rossi C; Morrison L; Sheehan J; Lefebvre P; Lopena O; Citrome L
    Adv Ther; 2021 Sep; 38(9):4900-4916. PubMed ID: 34368919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.